2024 annual financial data
Anika Therapeutics 2024 Operating margin
Direct answer
Operating margin was -4.25%.
Operating income was -5,101,000 USD and net income was -56,385,000 USD.
Operating cash flow was 5,403,000 USD.
Get free Anika Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 119,907,000 USD
- Operating income
- -5,101,000 USD
- Net income
- -56,385,000 USD
- Operating cash flow
- 5,403,000 USD